Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tisagenleucel

Roche Basel Switzerland

Roche claims its own CAR-T first with orphan drug Actemra

Comes as FDA approves the first CAR-T therapy from Novartis

- PMLiVE

Novartis claims first CAR-T approval, setting $475k price tag

Kymriah receives FDA nod to treat ALL patients

- PMLiVE

Gilead makes $11.9bn play for CAR-T specialist Kite

The agreement is due to close in this year’s fourth quarter

- PMLiVE

Intriguing data with Juno’s new CAR-T therapy

Suggests a long treatment effect from the biotech's JCAR017 candidate

- PMLiVE

Novartis claims EU approval for breast cancer drug Kisqali

Firm's CDK4/6 inhibitor can now challenge Pfizer's Ibrance in Europe

- PMLiVE

Novartis appoints Shaun Coughlin to lead its US biomedical research institute

The renowned academic joins as the pharma firm's global head of cardiovascular and metabolism

- PMLiVE

Novartis trial marks ResearchKit first in MS

ElevateMS study will allow participants to contribute from smartphones

- PMLiVE

Kite files first CAR-T candidate in Europe

But will need to play catch up in the US, where Novartis has a slight lead

- PMLiVE

Novartis and Bayer among backers for European big data project

The IMI's BigData@Heart programme will target cardiovascular research

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Race to CGRP migraine drug finish line enters the final straight

US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab

- PMLiVE

Alcon’s return to growth gives Novartis ‘options’, says CEO

Sales up 3% to $1.5bn in second quarter for ailing eyecare division

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links